NEO
$8.27
NeoGenomics, Inc.
Recent News
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.
3 Reasons to Avoid NEO and 1 Stock to Buy Instead
What a fantastic six months it’s been for NeoGenomics. Shares of the company have skyrocketed 48.3%, hitting $9.94. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
5 Insightful Analyst Questions From NeoGenomics’s Q4 Earnings Call
NeoGenomics’ fourth quarter results were met with a negative market reaction, despite revenue and non-GAAP earnings per share surpassing Wall Street’s expectations. Management attributed the quarter’s performance to continued growth in next-generation sequencing (NGS) test volumes, robust adoption of new products, and a deliberate shift away from lower-value, high-volume testing. CEO Anthony Zook noted, “Our clinical business continued its robust growth with revenue increasing 16% year over year
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness
Event context and recent share performance NeoGenomics (NEO) has been on many investors’ radars after a tough stretch in the share price, with negative returns over the past week, month and past 3 months adding to longer term weakness. See our latest analysis for NeoGenomics. At around US$9.89, NeoGenomics’ recent 7-day share price return of a 13.09% decline and year-to-date share price return of a 15.90% decline sit alongside a 1-year total shareholder return of a 10.90% decline, suggesting...
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)
NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.